The First Brazilian Cardiovascular Registry of Atrial Fibrillation: Primary Results of the RECALL Study.

BACKGROUND: It is estimated that atrial fibrillation (AF) affects approximately 1.5 million people in Brazil; however, epidemiological data are limited. We sought to evaluate the characteristics, treatment patterns, and clinical outcomes in patients with AF in Brazil by creating the first nationwide prospective registry. METHODS: RECALL was a multicenter, prospective registry that included and followed for 1 year 4,585 patients with AF at 89 sites across Brazil from April 2012 to August 2019. Patient characteristics, concomitant medication use, and clinical outcomes were analyzed using descriptive statistics and multivariable models. RESULTS: Of 4,585 patients enrolled, the median age was 70 (61, 78) years, 46% were women, and 53.8% had permanent AF. Only 4.4% of patients had a history of previous AF ablation and 25.2% had a previous cardioversion. The mean (SD) CHA2DS2-VASc score was 3.2 (1.6); median HAS-BLED score was 2 (2, 3). At baseline, 22% were not on anticoagulants. Of those taking anticoagulants, 62.6% were taking vitamin K antagonists and 37.4% were taking direct oral anticoagulants. The primary reasons for not using an oral anticoagulant were physician judgment (24.6%) and difficulty in controlling (14.7%) or performing (9.9%) INR. Mean (SD) TTR for the study period was 49.5% (27.5). During follow-up, the use of anticoagulants and INR in the therapeutic range increased to 87.1% and 59.1%, respectively. The rates/100 patient-years of death, hospitalization due to AF, AF ablation, cardioversion, stroke, systemic embolism, and major bleeding were 5.76 (5.12-6.47), 15.8 (14.6-17.0), 5.0 (4.4-5.7), 1.8 (1.4-2.2), 2.77 (2.32-3.32), 1.01 (0.75-1.36), and 2.21 (1.81-2.70). Older age, permanent AF, New York Heart Association class III/IV, chronic kidney disease, peripheral arterial disease, stroke, chronic obstructive pulmonary disease, and dementia were independently associated with increased mortality while the use of anticoagulant was associated with lower risk of death. CONCLUSIONS: RECALL represents the largest prospective registry of patients with AF in Latin America. Our findings highlight important gaps in treatment, which can inform clinical practice and guide future interventions to improve the care of these patients.

Colchicine to Reduce Atrial Fibrillation in the Postoperative Period of Myocardial Revascularization / Colchicina para Redução de Fibrilação Atrial em Pós-Operatório de Revascularização Miocárdica

Abstract Background: The high prevalence of atrial fibrillation (AF) in the postoperative period of myocardial revascularization surgery increases morbidity and mortality. Objective: To assess the efficacy of colchicine to prevent AF in the postoperative period of myocardial revascularization surgery, the impact of AF on hospital length of stay and death, and to identify its risk factors. Methods: Between May 2012 and November 2013, 140 patients submitted to myocardial revascularization surgery were randomized, 69 to the control group and 71 to the colchicine group. Colchicine was used at the dose of 1 mg orally, twice daily, preoperatively, and of 0.5 mg, twice daily, until hospital discharge. A single dose of 1 mg was administered to those admitted 12 hours or less before surgery. Results: The primary endpoint was AF rate in the postoperative period of myocardial revascularization surgery. Colchicine group patients showed no reduction in AF incidence as compared to control group patients (7.04% versus 13.04%, respectively; p = 0.271). There was no statistically significant difference between the groups regarding death from any cause rate (5.6% versus 10.1%; p = 0,363) and hospital length of stay (14.5 ± 11.5 versus 13.3 ± 9.4 days; p = 0.490). However, colchicine group patients had a higher infection rate (26.8% versus 8.7%; p = 0.007). Conclusion: The use of colchicine to prevent AF after myocardial revascularization surgery was not effective in the present study. Brazilian Registry of Clinical Trials number RBR-556dhr.

Resumo Fundamento: A alta prevalência de fibrilação atrial (FA) no pós-operatório de cirurgia de revascularização miocárdica ocasiona maior morbidade e mortalidade. Objetivos: Avaliar a eficácia da colchicina como profilaxia para FA no pós-operatório de cirurgia de revascularização miocárdica, o impacto da FA sobre o tempo de internação hospitalar e óbito e identificar fatores de risco para o seu aparecimento. Métodos: Entre maio de 2012 e novembro de 2013, 140 pacientes submetidos à cirurgia de revascularização miocárdica foram randomizados, 69 no grupo controle e 71 no grupo colchicina. A colchicina foi utilizada na dose de 1 mg via oral, duas vezes ao dia, no pré-operatório, e 0,5 mg, duas vezes ao dia, até a alta hospitalar. Dose única de 1 mg foi administrada aos internados 12 horas ou menos antes da cirurgia. Resultados: O desfecho primário foi a taxa de FA no pós-operatório de cirurgia de revascularização miocárdica. Os pacientes do grupo colchicina não apresentaram redução na incidência de FA em comparação aos do grupo controle (7,0% versus 13,0%, respectivamente; p = 0,271). Não houve diferença estatisticamente significativa entre os grupos em relação à taxa de óbito por qualquer causa (5,6% versus 10,1%; p = 0,363) e ao tempo de internação (14,5 ± 11,5 versus 13,3 ± 9,4 dias; p = 0,490). Porém, o grupo colchicina apresentou maior taxa de infecção (26,8% versus 8,7%; p = 0,007). Conclusões: O uso da colchicina para profilaxia da FA no pós-operatório de revascularização miocárdica não se mostrou eficaz neste estudo. Registro Brasileiro de Ensaios Clínicos número RBR-556dhr.

Colchicine to Reduce Atrial Fibrillation in the Postoperative Period of Myocardial Revascularization.

BACKGROUND: The high prevalence of atrial fibrillation (AF) in the postoperative period of myocardial revascularization surgery increases morbidity and mortality. OBJECTIVE: To assess the efficacy of colchicine to prevent AF in the postoperative period of myocardial revascularization surgery, the impact of AF on hospital length of stay and death, and to identify its risk factors. METHODS: Between May 2012 and November 2013, 140 patients submitted to myocardial revascularization surgery were randomized, 69 to the control group and 71 to the colchicine group. Colchicine was used at the dose of 1 mg orally, twice daily, preoperatively, and of 0.5 mg, twice daily, until hospital discharge. A single dose of 1 mg was administered to those admitted 12 hours or less before surgery. RESULTS: The primary endpoint was AF rate in the postoperative period of myocardial revascularization surgery. Colchicine group patients showed no reduction in AF incidence as compared to control group patients (7.04% versus 13.04%, respectively; p = 0.271). There was no statistically significant difference between the groups regarding death from any cause rate (5.6% versus 10.1%; p = 0,363) and hospital length of stay (14.5 ± 11.5 versus 13.3 ± 9.4 days; p = 0.490). However, colchicine group patients had a higher infection rate (26.8% versus 8.7%; p = 0.007). CONCLUSION: The use of colchicine to prevent AF after myocardial revascularization surgery was not effective in the present study. Brazilian Registry of Clinical Trials number RBR-556dhr.

[Radiofrequency catheter ablation of left accessory pathways by transeptal approach]. / Ablação por cateter com radiofreqüência de vias acessórias esquerdas por abordagem transeptal.

OBJECTIVE: To study a series of patients submitted to radiofrequency catheter ablation (RFA) of left accessory pathways (AP) using the transeptal approach (TSA) as compared to the conventional retrograde arterial approach (RAA). METHODS: One hundred consecutive patients (56 male; mean age of 34.3 +/- 11 years) with 100 left APs (62 overt and 38 concealed) underwent catheter ablation using the TS method (50 patients) and the RA method (50 patients) in an alternate fashion. The analysis was performed according to the intention-to-treat principle. RESULTS: The transeptal puncture was successfully performed in 48 patients (96%). This access allowed primary success in the ablation in all the patients without any complication. When we compared this approach with the RAA there was no difference as regards the primary success (p = 0.2), recurrence rate (p = 1.0), fluoroscopy time (p = 0.63) and total time (p = 0.47). One patient in the RAA group presented a vascular complication. The TSA allowed shorter ablation times (p=0.01) and smaller number of radiofrequency applications (p = 0.003) as compared to the conventional RAA. The patients who had recurrence and unsuccessful ablation in the first session in each approach underwent another session with the opposite technique (cross-over), with a final ablation success rate of 100%. CONCLUSION: The TS and RA approaches showed similar efficacy and safety for the ablation of left accessory pathways. The TSA allowed shorter ablation times and smaller number of radiofrequency applications. When the techniques were used in a complementary fashion, they increased the final efficacy of the ablation.

Ablação por cateter com radiofreqüência de vias acessórias esquerdas por abordagem transeptal / Radiofrequency catheter ablation of left accessory pathways by transeptal approach

OBJETIVO: Estudar uma série de pacientes submetidos a ablação por cateter, com radiofreqüência (RF) de vias acessórias (VA) esquerdas mediante abordagem transeptal (TS), comparando-os aos pacientes submetidos ao mesmo tipo de procedimento por abordagem arterial retrógrada (AR) convencional. MÉTODOS: Cem pacientes consecutivos (56 masculinos; 34,3 ± 11 anos de idade), portadores de 100 VA esquerdas (62 manifestas e 38 ocultas) foram submetidos a ablação por cateter por via TS (50 pacientes) e por via AR (50 pacientes), de forma alternada. A análise foi baseada na intenção de tratar. RESULTADOS: A punção transeptal foi realizada com sucesso em 48 (96 por cento) pacientes. Por esse acesso foi obtido sucesso primário na ablação em todos os pacientes e nenhuma complicação foi observada. Ao compararmos com o grupo AR não verificamos diferença em relação ao sucesso primário (p = 0,2), taxa de recorrências (p = 1,0), tempos de fluoroscopia (p = 0,63) e total (p = 0,47). No grupo AR um paciente apresentou complicação vascular. A abordagem TS proporcionou um menor tempo de ablação (p = 0,01) e número de aplicações de RF (p = 0,003) em relação à abordagem AR convencional. As recorrências e insucessos da primeira sessão de cada grupo foram submetidos a novo procedimento pela técnica oposta (cross-over), obtendo-se assim um sucesso final na ablação de 100 por cento. CONCLUSÃO: As abordagens TS e AR apresentam eficácia e segurança semelhantes para ablação de vias acessórias esquerdas. O tempo de ablação e o número de aplicações de RF foram menores com a abordagem TS. Quando as técnicas foram utilizadas de forma complementar, aumentaram a eficácia final da ablação.

Catheter ablation of atriofascicular Mahaim fibers guided by the activation potential.

OBJECTIVE: To determine whether recording of the activation potential may be used as an isolated criterion to guide catheter ablation of atriofascicular Mahaim fibers. METHODS: We studied 6 patients (5 females, mean age of 26 +/- 7.3 years) with paroxysmal tachycardias with a wide QRS complex, whose electrophysiological study diagnosed atriofascicular Mahaim fibers. Mapping and catheter ablation were performed in sinus rhythm, guided only by the recording of the activation potential of the fiber. RESULTS: Efficacy in ablation was achieved in all patients. The fibers were located in the right lateral region of the tricuspid ring in 3 patients, right posterolateral region in 2, and right anterolateral region in 1. A mean of 5.3 +/- 3 radiofrequency applications was performed. The mean fluoroscopy time was 46.6 +/- 25 minutes, and the mean duration of the procedure was 178.6 +/- 108 minutes. No complication occurred. In a mean 20-month follow-up, all patients were asymptomatic and receiving no antiarrhythmic drugs. CONCLUSION: Catheter ablation of Mahaim fibers may be performed with good safety and efficacy by mapping the activation potential of the tricuspid ring in sinus rhythm.

Ablaçäo por cateter de fibras atriofasciculares de Mahaim guiada pelo potencial de ativaçäo / Catheter ablation of atriofascicular Mahaim fibers guided by the activation potential

OBJECTIVE: To determine whether recording of the activation potential may be used as an isolated criterion to guide catheter ablation of atriofascicular Mahaim fibers. METHODS: We studied 6 patients (5 females, mean age of 26±7.3 years) with paroxysmal tachycardias with a wide QRS complex, whose electrophysiological study diagnosed atriofascicular Mahaim fibers. Mapping and catheter ablation were performed in sinus rhythm, guided only by the recording of the activation potential of the fiber. RESULTS: Efficacy in ablation was achieved in all patients. The fibers were located in the right lateral region of the tricuspid ring in 3 patients, right posterolateral region in 2, and right anterolateral region in 1. A mean of 5.3±3 radiofrequency applications was performed. The mean fluoroscopy time was 46.6±25 minutes, and the mean duration of the procedure was 178.6±108 minutes. No complication occurred. In a mean 20-month follow-up, all patients were asymptomatic and receiving no antiarrhythmic drugs. CONCLUSION: Catheter ablation of Mahaim fibers may be performed with good safety and efficacy by mapping the activation potential of the tricuspid ring in sinus rhythm

Procedimentos ablativos por cateter no tratamento da fibrilaçäo atrial / Catheter ablation for the treatment of atrial fibrillation

A alta prevalência da fibrilaçäo atrial, assim como sua morbidade e mortalidade, a ausência de terapêutica farmacológica segura e efetiva, e o entendimento cada vez maior de suas bases fisiopatológicas, tem estimulado o desenvolvimento de terapêuticas näo farmacológicas para a abordagem desta arritmia. Nos pacientes que apresentam fibrilaçäo atrial com alta resposta ventricular e refratária a drogas, a ablaçäo da junçäo AV, com implante de marcapasso, tem se mostrado uma alternativa efetiva, no entanto, restrita ao controle da freqüência cardíaca. A modificaçäo do nó AV pode ser utilizada como primeira tentativa para o controle da freqüência, antes da opçäo definitva, representada pela ablaçäo da junçäo AV. As técnicas propostas de ablaçäo por cateter, baseadas na cirurgia de Cox, carecem de maior esclarecimentos da fisiopatologia da fibrilaçäo atrial, assim como de avanços tecnológicos relacionados aos cateteres e as novas fontes de energia, para que se desenvolvam técnicas mais eficazes, seguras, e de maior aplicabilidade prática. A ablaçäo de focos deflagradores da fibrilaçäo atrial, embora em fase de investigaçäo em relaçäo a sua real eficácia e margem de complicaçöes, traz a expectativa de cura da chamada fibrilaçäo atrial focal